StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Equities research analysts at StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NYSE:NBY opened at $0.63 on Monday. NovaBay Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $9.08. The stock has a market cap of $3.33 million, a P/E ratio of -0.01 and a beta of 0.73. The stock has a 50-day simple moving average of $0.66 and a 200-day simple moving average of $0.63.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.